Clear Street Group Inc. Takes Position in Drugs Made In America Acquisition II Corp. $DMII

Clear Street Group Inc. purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 181,521 shares of the company’s stock, valued at approximately $1,797,000.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC purchased a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $265,000. ABC Arbitrage SA purchased a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $396,000. Deltec Asset Management LLC bought a new position in Drugs Made In America Acquisition II during the fourth quarter valued at approximately $495,000. Quarry LP bought a new position in Drugs Made In America Acquisition II during the fourth quarter valued at approximately $990,000. Finally, DLD Asset Management LP bought a new position in Drugs Made In America Acquisition II during the fourth quarter valued at approximately $1,111,000.

Drugs Made In America Acquisition II Stock Performance

Shares of Drugs Made In America Acquisition II stock opened at $10.09 on Monday. The firm’s 50 day moving average is $10.03. Drugs Made In America Acquisition II Corp. has a twelve month low of $9.86 and a twelve month high of $10.09.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.